Increase in eosinophil-derived neurotoxin level in school children with allergic disease.
Allergic rhinitis
Atopic dermatitis
Biomarkers
Bronchial asthma
Eosinophil-derived neurotoxin
Food allergy
Journal
Asia Pacific allergy
ISSN: 2233-8276
Titre abrégé: Asia Pac Allergy
Pays: Netherlands
ID NLM: 101561954
Informations de publication
Date de publication:
Jul 2022
Jul 2022
Historique:
received:
02
06
2022
accepted:
12
07
2022
entrez:
15
8
2022
pubmed:
16
8
2022
medline:
16
8
2022
Statut:
epublish
Résumé
Eosinophils are major effector cells of allergic disease and excellent markers of eosinophilic inflammation. Accurate and reliable biomarkers are helpful in the diagnosis, treatment, and control of allergic disease. This study aimed to investigate an alternate marker of eosinophilic inflammation, eosinophil-derived neurotoxin (EDN), in a number of allergic diseases. Three hundred ninety-six elementary school-age children with various allergic conditions were recruited for this study. Subgroups included food allergies (FAs), atopic dermatitis (AD), bronchial asthma (BA), and allergic rhinitis (AR). EDN levels in these groups were compared to those in 93 healthy controls (HC). All subjects with allergic disease had elevated levels of serum EDN (median [interquartile range]: FA, 124.2 ng/mL [59.13-160.5 ng/mL]; AD, 110.8 ng/mL [57.52-167.9 ng/mL]; BA, 131.5 ng/mL [60.60-171.0 ng/mL]; AR, 91.32 ng/mL [46.16-145.0 ng/mL]) compared to HC (38.38 ng/mL [32.40-55.62 ng/mL]) ( Direct measures of eosinophilic inflammation are needed for accurate diagnosis, treatment, and monitoring of allergic diseases. EDN may be a worthy biomarker of eosinophil activity and a useful screening tool for allergic diseases including FA, AD, BA, and AR.
Sections du résumé
Background
UNASSIGNED
Eosinophils are major effector cells of allergic disease and excellent markers of eosinophilic inflammation. Accurate and reliable biomarkers are helpful in the diagnosis, treatment, and control of allergic disease.
Objective
UNASSIGNED
This study aimed to investigate an alternate marker of eosinophilic inflammation, eosinophil-derived neurotoxin (EDN), in a number of allergic diseases.
Methods
UNASSIGNED
Three hundred ninety-six elementary school-age children with various allergic conditions were recruited for this study. Subgroups included food allergies (FAs), atopic dermatitis (AD), bronchial asthma (BA), and allergic rhinitis (AR). EDN levels in these groups were compared to those in 93 healthy controls (HC).
Results
UNASSIGNED
All subjects with allergic disease had elevated levels of serum EDN (median [interquartile range]: FA, 124.2 ng/mL [59.13-160.5 ng/mL]; AD, 110.8 ng/mL [57.52-167.9 ng/mL]; BA, 131.5 ng/mL [60.60-171.0 ng/mL]; AR, 91.32 ng/mL [46.16-145.0 ng/mL]) compared to HC (38.38 ng/mL [32.40-55.62 ng/mL]) (
Conclusions
UNASSIGNED
Direct measures of eosinophilic inflammation are needed for accurate diagnosis, treatment, and monitoring of allergic diseases. EDN may be a worthy biomarker of eosinophil activity and a useful screening tool for allergic diseases including FA, AD, BA, and AR.
Identifiants
pubmed: 35966157
doi: 10.5415/apallergy.2022.12.e25
pmc: PMC9353201
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e25Informations de copyright
Copyright © 2022. Asia Pacific Association of Allergy, Asthma and Clinical Immunology.
Déclaration de conflit d'intérêts
Conflict of Interest: The authors have no financial conflicts of interest.
Références
Lung. 2007 Mar-Apr;185(2):97-103
pubmed: 17393238
Allergy Asthma Immunol Res. 2018 Nov;10(6):686-697
pubmed: 30306750
Cochrane Database Syst Rev. 2017 Aug 24;8:CD005603
pubmed: 28837221
Clin Exp Allergy. 1991 Sep;21(5):561-7
pubmed: 1742647
Allergol Int. 2017 Jan;66(1):70-74
pubmed: 27329145
Am J Respir Crit Care Med. 2000 Jan;161(1):64-72
pubmed: 10619799
J Pediatr. 2010 May;156(5):749-54
pubmed: 20171653
Adv Immunol. 1986;39:177-253
pubmed: 3538819
J Asthma. 2010 Jun;47(5):568-73
pubmed: 20560830
J Allergy Clin Immunol. 2009 Jun;123(6):1408-11.e1
pubmed: 19447482
J Dermatol Sci. 2001 May;26(1):79-82
pubmed: 11323224
Allergy. 2004 Jan;59(1):26-32
pubmed: 14674929
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2009 Jan;44(1):16-20
pubmed: 19484982
Eur Respir J. 2000 Mar;15(3):491-7
pubmed: 10759442
Int Arch Allergy Immunol. 2000 May;122(1):49-57
pubmed: 10859469
Chest. 1997 Feb;111(2 Suppl):11S-16S
pubmed: 9042022
Thorax. 1996 May;51(5):496-502
pubmed: 8711677
J Asthma. 2008 Nov;45(9):754-7
pubmed: 18972290
J Allergy Clin Immunol. 2003 Mar;111(3 Suppl):S799-804
pubmed: 12618746
Biomarkers. 2013 May;18(3):230-5
pubmed: 23557131
Clin Exp Allergy. 2008 May;38(5):709-50
pubmed: 18384431